Acute hyponatremia causes swelling of brain cells and, if of a sufficient degree, increased intracranial pressure. This is a consequence of the relative impermeability of the blood-brain barrier to sodium ions 1 ; this principle underlies the clinical utility of hypertonic NaCl infusion in the treatment of the cerebral edema accompanying traumatic brain injury or stroke. That acute hyponatremic brain swelling should cause neurologic symptoms is unsurprising. Brain swelling is absent in chronic hyponatremia, in contrast, and the basis for the neurologic and cognitive symptoms in this context is less clear.There is an emerging view that even mild-to-moderate degrees of chronic hyponatremia cause neurologic symptoms and that reversal of hyponatremia ameliorates them. 2 Data in support of this attractive hypothesis are few. Renneboog et al. tested gait and coordination in 16 patients with syndrome of inappropriate antidiuresis (SIAD) both on and off their chronic therapy (with mean plasma sodium concentrations of 138 and 128 mEq/L, respectively). 3 They reported that the total traveled way, an index of balance performance and gait instability, was abnormal under hyponatremic conditions but normalized after correction of hyponatremia. All participants were outpatients at the time of evaluation; therefore, there was no confounding by acute medical comorbidity. To eliminate an additional potential source of bias, and in support of reversibility, half were initially tested on treatment, and half were tested in the untreated state.Additional evidence comes from the Study of Ascending Levels of Tolvaptan in Hyponatremia-I (SALT-I) and SALT-II trials. 4 These studies tested the effect of the vasopressin V 2 -receptor antagonist, tolvaptan, on plasma sodium concentration in hyponatremic participants with an initial plasma sodium concentration ,135 mEq/L. One secondary end point was a 12-Item Short Form Health Survey (SF-12) score. The SF-12 is a proprietary instrument that quantifies study participants' self-reported well-being using 12 general questions addressing mood and health-related limitations on activity. 5 After 30 days of tolvaptan treatment, during which the mean plasma sodium concentration increased from 129 to 136 mEq/L, the mental component of the SF-12 score significantly improved (P50.02), whereas the physical component was unaffected. This metric is subjective (i.e., self-reported) and emphasizes feelings of depression and anxiety; it does not directly assess cognitive performance or neurologic deficit. In addition, there was no control for the order of treatment; all participants were initially tested when hyponatremic and then tested again after tolvaptan treatment. Nonetheless, these findings in a moderately large randomized controlled trial are consistent with a reversible neuropsychiatric effect of even mild hyponatremia.Furthermore, in population-based studies, chronic hyponatremia associates with bone fracture risk 6-8 ; however, whether this is a consequence of a neurologic phenotype predisposing to...